MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.09
+0.02
+0.28%
Closed 16:05 09/30 EDT
OPEN
7.11
PREV CLOSE
7.07
HIGH
7.27
LOW
7.00
VOLUME
333.09K
TURNOVER
--
52 WEEK HIGH
11.38
52 WEEK LOW
3.500
MARKET CAP
316.21M
P/E (TTM)
-3.1132
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Aeglea BioTherapeutics (NASDAQ:AGLE) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 09/11 11:39
Aeglea BioTherapeutics to Participate in September Investment Conferences
AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in three investor
GlobeNewswire · 09/02 21:05
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations
GlobeNewswire · 08/18 21:05
Aeglea BioTherapeutics EPS beats by $0.03
Aeglea BioTherapeutics (NASDAQ:AGLE): Q2 GAAP EPS of -$0.40 beats by $0.03. Cash, cash equivalents, marketable securities and restricted cash of $159.2M. P
seekingalpha · 08/10 17:42
Aeglea BioTherapeutics Q2 EPS $(0.40) Beats $(0.44) Estimate
Aeglea BioTherapeutics (NASDAQ:AGLE) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.44) by 9.09 percent. This is a 27.27 percent increase over losses of $(0.55) per share
Benzinga · 08/10 12:49
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177 for the Treatment of HomocystinuriaAUSTIN, Texas, Aug. 10, 20
GlobeNewswire · 08/10 12:30
Were Hedge Funds Right About Buying Aeglea BioTherapeutics, Inc. (AGLE)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 06/30 16:05
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)
Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 06/29 16:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGLE. Analyze the recent business situations of Aeglea Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGLE stock price target is 16.71 with a high estimate of 26.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 114
Institutional Holdings: 39.51M
% Owned: 88.59%
Shares Outstanding: 44.60M
TypeInstitutionsShares
Increased
43
11.33M
New
33
6.48M
Decreased
13
400.63K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.50%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Independent Director
Russell Cox
President/Chief Executive Officer/Director
Anthony Quinn
Chief Financial Officer/Vice President
Charles York
Chief Operating Officer
Leslie Sloan
Other
Michael Hanley
Other
Ravi Rao
Independent Director
Suzanne Bruhn
Director/IR Contact Officer
Joey Perrone
Independent Director
V. Bryan Lawlis
Independent Director
Ivana Magovcevic-Liebisch
Director
Bryan Lawlis
Independent Director
Sandesh Mahatme
Independent Director
Armen Shanafelt
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.